414 related articles for article (PubMed ID: 16951477)
21. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates and atypical femoral fractures: a time for reflection.
Compston JE
Maturitas; 2010 Jan; 65(1):3-4. PubMed ID: 19932574
[No Abstract] [Full Text] [Related]
23. [Accumulation of microdamage in bone].
Mori S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():203-8. PubMed ID: 18161107
[No Abstract] [Full Text] [Related]
24. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
25. Is there an advantage to an injected bisphosphonate versus a daily or monthly oral regimen?
Mayo Clin Womens Healthsource; 2008 Sep; 12(9):8. PubMed ID: 18667976
[No Abstract] [Full Text] [Related]
26. Effects of ibandronate on bone quality: preclinical studies.
Bauss F; Dempster DW
Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333
[TBL] [Abstract][Full Text] [Related]
27. Consultation corner. Bone loss drug gives users a break.
Bellantoni M
Johns Hopkins Med Lett Health After 50; 2007 Dec; 19(10):6. PubMed ID: 18225340
[No Abstract] [Full Text] [Related]
28. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
29. What to make of the new warning on bisphosphonates. Officials acknowledge a connection between the most popular bone drugs and rare thigh fractures.
Harv Womens Health Watch; 2010 Dec; 18(4):6-7. PubMed ID: 21268797
[No Abstract] [Full Text] [Related]
30. [Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
Asano S; Suzuki A; Itoh M
Clin Calcium; 2009 Aug; 19(8):1179-85. PubMed ID: 19638702
[TBL] [Abstract][Full Text] [Related]
31. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
[TBL] [Abstract][Full Text] [Related]
32. [Long-term and high-dose bisphosphonate administration causes no bone over-mineralization].
Liu C; Cao YP; Yang X; Mashiba T; Mori S
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2968-71. PubMed ID: 20137705
[TBL] [Abstract][Full Text] [Related]
33. [Diabetes mellitus and bisphosphonate-related osteonecrosis of the jaws].
Urade M
Clin Calcium; 2009 Sep; 19(9):1332-8. PubMed ID: 19721206
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
35. What is new in the treatment of steroid-induced osteoporosis?
Liu RH; Werth VP
Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Schneider JP
Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
[TBL] [Abstract][Full Text] [Related]
37. [Atypical femoral fractures in long-term osteoporotic treatment with bisphosphonates].
Thein R; Tenenbaum S; Chechick O; Hershkovitz O; Chechik A; Caspi I
Harefuah; 2012 Sep; 151(9):532-6, 555. PubMed ID: 23367748
[TBL] [Abstract][Full Text] [Related]
38. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
Friedrich RE; Blake FA
Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Cruse LM; Valeriano J; Vasey FB; Carter JD
J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
Ruggiero SL; Fantasia J; Carlson E
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
